Company Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.
The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma.
It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma.
Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial.
Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
| Country | United Kingdom |
| Founded | 2008 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 497 |
| CEO | Bahija Jallal |
Contact Details
Address: 92 Park Drive, Milton Park Abingdon, OX14 4RY United Kingdom | |
| Phone | 44 12 3543 8600 |
| Website | immunocore.com |
Stock Details
| Ticker Symbol | IMCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $26.00 |
| CIK Code | 0001671927 |
| CUSIP Number | 45258D105 |
| ISIN Number | US45258D1054 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bahija Jallal Ph.D. | Chief Executive Officer and Executive Director |
| Brian R. Di Donato M.B.A. | Executive Vice President, Chief Financial Officer and Strategy |
| Tina St. Leger | Chief Human Resources Officer |
| Dr. David Berman M.D., Ph.D. | Executive Vice President of Research and Development |
| John Trainer M.B.A. | SVice President and Chief Operating Officer |
| John Goll III | SVice President, Finance and Chief Accounting Officer |
| Annelise Vuidepot Ph.D. | Senior Vice President, Chief Technology Officer and Research and UK Site Lead |
| Sean D. Buckley | Vice President and Chief Information Officer |
| Clayton Robertson | Head of Investor Relations |
| Lily Margaret Hepworth | Senior Vice President, General Counsel and Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 8-K | Current Report |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 8-K | Current Report |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Sep 16, 2024 | 8-K | Current Report |
| Sep 10, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |